In addition, TRAIL showed synergistic antileukemic effects with VEN in AML cells with high levels of TP53INP2 in vitro, a result that was further confirmed using an AML patient-derived xenograft (PDX) model. Here, TP53INP2 is linked to acute myeloid leukemia.